Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2022-01-05 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
华英证券有限责任公司关于深圳信立泰药业股份有限公司2021年度持续督导现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2021年度持续督导现场检查报告" which translates to "2021 Annual Continuous Supervision On-site Inspection Report" by 华英证券有限责任公司 (a securities company) for 深圳信立泰药业股份有限公司. The content details the on-site inspection of company governance, internal control, information disclosure, protection of company interests, use of raised funds, performance, shareholder commitments, and other important matters. It includes detailed findings and compliance checks but does not contain financial statements or typical annual report data. The document is a standalone audit or inspection report related to regulatory supervision and compliance rather than a full annual report or earnings release. It is not a brief announcement or a certification letter but a substantive report on internal controls and governance. Therefore, it fits best under Audit Report / Information (AR). The document length is 4233 characters, which is substantive enough to be a report rather than a mere announcement. FY 2021
2022-01-05 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, compliance with relevant laws and regulations, and the company's plans to continue the repurchase within the authorized limits. The document does not contain financial statements or comprehensive financial data but focuses on the update of the share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buying back or selling its own shares.
2022-01-04 Chinese
关于恩那司他片上市申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (706 characters) from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the acceptance of a drug listing application by the National Medical Products Administration. It contains no financial data, no detailed report, and no mention of financial results or management discussion. It is an official notice about regulatory acceptance of a drug application, not a financial report or detailed filing. The document is an announcement of a regulatory event related to product approval, fitting best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2022-01-03 Chinese
第五届监事会第十八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the approval of an asset impairment provision. It includes details about the meeting date, attendance, and the decision made. The document is short (650 characters) and serves as an official announcement of a board decision rather than a full financial report or audit. It does not contain financial statements or detailed financial analysis. It is not a report publication announcement since it contains the resolution text itself, not just a notice of report availability. The content fits best under Regulatory Filings (RNS) as it is a formal regulatory announcement about a corporate governance decision without fitting other more specific categories.
2022-01-03 Chinese
第五届董事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board meeting of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the appointment of a new financial officer and the approval of asset impairment provisions. The document includes statements about compliance with company law and stock exchange guidelines, and mentions independent directors' opinions. It is a formal announcement of board decisions rather than a full management report or financial report. The content fits the category of Board/Management Information (MANG), as it concerns changes in senior management and board resolutions. The document length is short (1697 characters), consistent with an announcement rather than a full report.
2022-01-03 Chinese
关于计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the provision for asset impairment. It details the decision made by the board of directors to recognize an impairment loss on intangible assets related to a subsidiary, including the amount, reasons, and accounting standards applied. The document includes board and supervisory opinions and states that the impairment provision does not require shareholder approval. The document length is 2701 characters, which is relatively short and primarily serves as a formal announcement of a specific accounting action rather than a full financial report or audit report. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for announcements that do not fit other specific categories and are not full reports themselves.
2022-01-03 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.